Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
N/A
2(50.0%)
4Total
Phase 1(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06862388Phase 1Not Yet Recruiting

Stem Cell Therapy for Intracerebral Hemorrhage

Role: collaborator

NCT06463847Phase 1Recruiting

Phase I Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis

Role: collaborator

NCT04562025Not ApplicableUnknown

Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy

Role: collaborator

NCT04293692Not ApplicableWithdrawn

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Role: collaborator

All 4 trials loaded